StreetInsider.com News Articles

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

BOSTON--(BUSINESS WIRE)-- EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, in collaboration with President Trump’s administration, announced new patient access pathways to make its complete portfolio of infertility medications used for in

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

Fri, 06 Feb 2026 08:00:00 -0500

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com
New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”

Not intended for media outside the U.S. or Canada

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

BOSTON--(BUSINESS WIRE)-- EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib.

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Mon, 12 Jan 2026 14:00:00 -0500

Not intended for media outside the U.S. or Canada

“With pimicotinib, we have an opportunity to significantly